RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration

We appreciate the important contribution of Tibau et al. (1) in evaluation of the magnitude of clinical benefit of US Food and Drug Administration (FDA)–approved anticancer agents. The authors report the proportion of FDA-approved indications meeting the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) v1.0 threshold of scores for substantial clinical benefit (A and B for curative treatments or 4 or 5 for noncurative treatments, which the authors have used as a threshold for "meaningful clinical benefit").

http://ift.tt/2GouBCk